Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00
Status: | Active, not recruiting |
---|---|
Conditions: | Ocular |
Therapuetic Areas: | Ophthalmology |
Healthy: | No |
Age Range: | 22 - Any |
Updated: | 4/14/2017 |
Start Date: | September 7, 2015 |
End Date: | June 30, 2017 |
Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00
The purpose of this study is to investigate visual outcomes and assess safety at 12 months
(330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™
Presbyopia-Correcting IOL.
(330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™
Presbyopia-Correcting IOL.
This study will be conducted in regions where the test article is approved at the time of
study start.
study start.
Inclusion Criteria:
- Diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification
with a clear cornea incision;
- Able to comprehend and willing to sign informed consent and complete all required
postoperative follow-up procedures;
- Clear intraocular media other than cataract in both eyes;
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Clinically significant corneal abnormalities including corneal dystrophy,
inflammation or edema;
- Ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or
color vision deficiencies;
- Glaucoma (uncontrolled or controlled with medication) or ocular hypertension;
- Pregnant or lactating;
- Expected to require ocular surgical or retinal laser treatment;
- Other protocol-specified exclusion criteria may apply.
We found this trial at
1
site
Click here to add this to my saved trials